Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:AMGN News 15 December 2025 - 5 February 2026

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen stock pulled back after a six-day run — here’s what investors watch next week

Amgen shares fell 0.7% to $344.75 Friday, ending a six-day winning streak after reaching a 52-week high of $349.98 on Thursday. The stock remains up about 4% for the week. Investors are awaiting the Feb. 3 earnings call for updates on Amgen’s obesity drug pipeline and guidance. The board approved a $2.52 quarterly dividend, payable March 6 to shareholders of record by Feb. 13.
24 January 2026
·
Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen shares fell 1.21% to $326.10 Friday, marking a second straight day of losses as the S&P 500 rose. Trading volume reached about 3.7 million shares. Truist maintained a “hold” rating and slightly raised its price target. Investors are watching next week’s J.P. Morgan Healthcare Conference and Amgen’s Feb. 3 earnings report.
10 January 2026
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus

Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus

NEW YORK, December 29, 2025, 22:14 ET — Market closed Amgen shares fell 1% on Monday, ending the session down $3.30 at $329.63. StockAnalysis The decline matters now because traders are heading into the final sessions of the year with U.S. indexes near record territory and liquidity thinner than usual. That backdrop can amplify moves in large-cap healthcare stocks even without a company-specific trigger. Reuters Wall Street’s main indexes closed lower, led by a retreat in heavyweight technology names, Reuters reported. “It’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford
30 December 2025
···
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Inc. (NASDAQ: AMGN) ended Monday, December 22, 2025, modestly higher, but the more important story for Tuesday’s open is what hit after the closing bell: fresh FDA approvals for new denosumab biosimilars that reference Amgen’s blockbuster bone-drug franchises Prolia and XGEVA—plus a credit-rating upgrade from Fitch that underscores improving balance-sheet flexibility. Below is a complete, investor-focused rundown of what moved (and what could move) Amgen stock before the U.S. market opens Tuesday, December 23, 2025. AMGN stock recap: where Amgen closed and what after-hours traders saw Amgen shares finished the regular session at $331.39, up about 1.2% on the
23 December 2025
···
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Inc. (NASDAQ: AMGN) is back in the spotlight on Monday, December 22, 2025, as investors weigh a wave of White House drug‑pricing agreements, a fast‑moving “most‑favored‑nation” (MFN) pricing push, and what it could all mean for Amgen’s earnings power in 2026. The stock traded higher in Monday’s session, with market data showing shares around $331. While the headlines are centered on drug prices, the market’s reaction has been notably measured: several analyst notes published today suggest these deals may be designed to reduce political and tariff uncertainty more than they materially compress pharma profits—at least in the near term.
22 December 2025
··
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen Inc. (NASDAQ: AMGN) heads into the Christmas-shortened trading week with a fresh wave of policy headlines, a newly expanded FDA label win in rare disease, and a market still laser-focused on what comes next for its obesity pipeline. Shares last traded around $327.38, following a session that ranged roughly between $323 and $331—levels that now matter even more in holiday-thinned liquidity. This coming week is also structurally different for U.S. equities: the NYSE closes early at 1:00 p.m. ET on Wednesday, Dec. 24, 2025 and is closed on Thursday, Dec. 25, 2025. That reduced time window can amplify single
21 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
········
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. (NASDAQ: AMGN) is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA approvals that expand the growth runway, reaffirmed shareholder returns via dividends, and a split—but active—Wall Street outlook heading into 2026. AMGN last traded around $327.38, reflecting the most recent available market print (U.S. markets are closed today). Below is a detailed, publication-ready breakdown of today’s key Amgen stock news, along with forecasts and analyst analysis relevant as of 20.12.2025. What’s
20 December 2025
·
Amgen Stock (AMGN) News Today, Dec. 16, 2025: Dividend Boost, FDA Wins, Analyst Targets, and Key 2026 Catalysts

Amgen Stock (AMGN) News Today, Dec. 16, 2025: Dividend Boost, FDA Wins, Analyst Targets, and Key 2026 Catalysts

Amgen Inc. (NASDAQ: AMGN) is in focus on December 16, 2025, as investors weigh a fresh dividend raise, recent regulatory momentum, and a pipeline narrative that stretches from cardiovascular outcomes to the high-stakes obesity race. As of Dec. 16, 2025 (18:00 UTC), Amgen shares traded around $324.36, slightly lower on the day, with an intraday range roughly between $323.05 and $326.03. While price action is calm, the story around AMGN is busy—especially for long-term investors looking for a blend of income, defensiveness, and late-stage catalysts. What’s driving Amgen stock on Dec. 16: dividends back in the spotlight A key theme
16 December 2025
··
Amgen (AMGN) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Amgen (AMGN) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Amgen Inc. (NASDAQ: AMGN) heads into Monday’s session (Dec. 15, 2025) after a news-heavy stretch that has reinforced two familiar pillars of the large-cap biotech story: a steady capital-return profile and a pipeline/label-expansion engine that can still surprise to the upside. As of the latest available close, Amgen shares were around $317.74, down $1.19 (-0.37%) from the prior close, with a 52-week range of roughly $230.10 to $346.38 and a market capitalization near $171 billion. Below is a detailed pre-market guide to the latest headlines, near-term catalysts, analyst forecasts, and the key risks investors are weighing before the opening bell.
15 December 2025
·
1 2

Stock Market Today

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

7 February 2026
Coca-Cola will discontinue its frozen products, including the Minute Maid frozen line, in the U.S. and Canada in Q1 2026. Shares closed Friday up 0.66% at $79.03 ahead of Tuesday’s quarterly results. CEO James Quincey sold 337,824 shares on Feb. 3 for about $26 million under a pre-arranged plan. Options pricing suggests a possible 3% move after earnings.
Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

7 February 2026
Cisco shares closed up 3% at $84.82 Friday after a volatile week for tech stocks. The company will report quarterly results Feb. 11, with analysts expecting EPS of $1.02 on $15.12 billion revenue. U.S. jobs and inflation data, delayed by the federal shutdown, are also due next week. About 23.9 million Cisco shares traded Friday.
AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, rebounding after a 13% plunge earlier in the week on weak guidance and AI competition fears. The Philadelphia semiconductor index rose 5.7% as chip stocks led a broader market rally. Investors are awaiting next week’s U.S. payrolls and inflation data, which could shift rate expectations for tech.
Go toTop